A new entity controlled by Strides will be formed following the transaction. The businesses of Strides and Apotex will run independently under the Arrow and Apotex brands respectively.
The merger will help Strides to increase its revenue in the Australian generic pharmaceutical market.
The acquisition was finalised after revising Takeda’s fourth proposal of £44.3bn ($59.96bn). Three previous proposal offers were made by Takeda for the acquisition of Shire for £41bn ($55.49bn), £43bn ($58.2bn) and £44bn ($59.55bn).
Shire will become a subsidiary of Takeda and will own approximately half of the combined group, as per the acquisition.
The acquisition will help Takeda in delivering rare disease and plasma-derived therapies and also boost oncology drugs and vaccine development.
The headquarters of the combined company will be located in Japan, upon completion of the acquisition in the first half of 2019.
US-based pharmaceutical company Eli Lilly and Company (Lilly) has agreed to acquire Armo Biosciences for $1.6bn.
Eli Lilly will buy each share of ARMO Biosciences for $50 in cash, as per the terms of the agreement.
The acquisition will help Eli Lilly to further improve its clinical portfolio adding ARMO Biosciences’ lead immuno-oncology asset pegilodecakin to its portfolio.
Eli Lilly has appointed Credit Suisse (USA) as financial adviser, and Wachtell, Lipton, Rosen & Katz as legal adviser for the transaction.
ARMO has appointed Centerview Partners as financial adviser.
Jefferies has been appointed as financial adviser, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian as legal adviser to ARMO.